La vendita allo scoperto per Akebia Therapeutics dà agli investitori un'idea del grado in cui gli investitori stanno scommettendo sul declino delle azioni di Akebia Therapeutics. I dati relativi alle vendite allo scoperto vengono aggiornati ogni due settimane.

Akebia Therapeutics (NASDAQ:AKBA) Azioni, Report sulle vendite allo scoperto

Akebia Therapeutics

Akebia Therapeutics Inc is a fully integrated biopharmaceutical company. The Company's operating segment is the business of developing and commercializing novel therapeutics for people with kidney disease. The current portfolio of the company includes Auryxia (ferric citrate), a medicine approved and marketed in the United States for the control of serum phosphorus levels in adult patients with dialysis-dependent chronic kidney disease and the treatment of iron deficiency anemia, in adult patients with non-dialysis-dependent chronic kidney disease, Vafseo (vadadustat), an oral hypoxia-inducible factor prolyl hydroxylase, inhibitor, is approved in Japan for the treatment of anemia due to chronic kidney disease, in adult patients, HIF-PH inhibitors in preclinical development.

Akebia Therapeutics Inc

AKBANK T/A/S GDR 144A by Akbank Turk Anonim Sirketi

Akbank TAS

AKBANK T/A/S S/ADR by Akbank Turk Anonim Sirketi

Akebia continues to publish important results of FO2CUS trial to further physicians' understanding of Vafseo&#xAE; (vadadustat)&nbsp;
CAMBRIDGE, Mass., Nov. 14, 2024 /PRNewswire/ -- <a href="https://c212.net/c/link/?t=0&amp;l=en&amp;o=4302749-1&amp;h=57348715&amp;u=https%3A%2F%2Fakebia.com%2F&amp;a=Akebia+Therapeutics%C2%AE%2C+Inc.">Akebia Therapeutics&#xAE;, Inc.</a> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AKBA#NASDAQ">AKBA</a>), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, today announced that the <a href="https://c212.net/c/link/?t=0&amp;l=en&amp;o=4302749-1&amp;h=3875030076&amp;u=https%3A%2F%2Fwww.ajkd.org%2F&amp;a=American+Journal+of+Kidney+Disease">American Journal of Kidney Disease</a> has published the results of FO2CUS, an open-label study evaluating the efficacy and safety of vadadustat, an oral hypoxia-inducible factor prolyl hydroxylase (HIF-PH) inhibitor, in hemodialysis patients who were converted from a long-acting erythropoiesis-stimulating agent (ESA) to three times weekly oral vadadustat dosing for the maintenance treatment of anemia.
<a href="https://mma.prnewswire.com/media/1136400/Akebia_Logo.html">AKBA</a>), a biopharmaceutical company focused on the development and commercialization of therapeutics for people living with kidney disease (PRNewsfoto/Akebia Therapeutics, Inc.)" alt="Akebia Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AKBA#NASDAQ">AKBA</a>), a biopharmaceutical company focused on the development and commercialization of therapeutics for people living with kidney disease (PRNewsfoto/Akebia Therapeutics, Inc.)"&gt;
The article titled, "Vadadustat Three Times Weekly in Patients With Anemia Due to Dialysis-Dependent CKD," is available <a href="https://c212.net/c/link/?t=0&amp;l=en&amp;o=4302749-1&amp;h=3468772615&amp;u=https%3A%2F%2Fwww.ajkd.org%2Farticle%2FS0272-6386(24)01043-6%2Ffulltext&amp;a=here">here</a>.

Biotech

News

General

AKBA

Akebia Therapeutics Announces That The American Journal Of Kidney Disease Has Published The Results Of FO2CUS, An Open-Label Study Evaluating The Efficacy And Safety Of Vadadustat, An Oral Hypoxia-Inducible Factor Prolyl Hydroxylase Inhibitor, In Hemodialysis Patients Who Were Converted From A Long-Acting Erythropoiesis-stimulating Agent To 3-Times Weekly Oral Vadadustat Dosing For The Maintenance Treatment Of Anemia

WIIM

Akebia Therapeutics shares are trading lower after the company reported worse-than-expected Q3 financial results.

Akebia Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AKBA#NASDAQ">AKBA</a>) reported quarterly losses of $(0.10) per share which missed the analyst consensus estimate of $(0.06) by 66.67 percent. The company reported quarterly sales of $32.400 million which missed the analyst consensus estimate of $44.507 million by 27.20 percent. This is a 22.94 percent decrease over sales of $42.046 million the same period last year.

Earnings

Earnings Misses

Akebia Therapeutics Q3 2024 GAAP EPS $(0.10) Misses $(0.06) Estimate, Sales $32.400M Miss $44.507M Estimate

HC Wainwright &amp; Co. analyst Ed Arce reiterates Akebia Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AKBA#NASDAQ">AKBA</a>) with a Buy and maintains $7.5 price target.

Price Target

Reiteration

Analyst Ratings

HC Wainwright & Co. Reiterates Buy on Akebia Therapeutics, Maintains $7.5 Price Target

Akebia Therapeutics shares are trading higher after the company announced it signed a multi-year commercial contract with one of the nation's leading providers of kidney care services. Allowing the company to expand access to Vafseo for patients on dialysis by enabling physicians to prescribe it as clinically appropriate.

Contract in place with a comprehensive kidney care provider serving more than 200,000 patients at its thousands of U.S. dialysis centers&nbsp;
CAMBRIDGE, Mass., Oct. 22, 2024 /PRNewswire/ -- Akebia Therapeutics&#xAE;, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AKBA#NASDAQ">AKBA</a>), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, today announced that it has signed a multi-year commercial contract with one of the nation's leading providers of kidney care services, expanding access to Vafseo&#xAE; (vadadustat) for patients on dialysis. The contract enables physicians to prescribe Vafseo to patients on dialysis as deemed clinically appropriate. Akebia expects Vafseo will be available in the U.S. in January 2025.

Akebia Therapeutics Signs A Multi-Year Commercial Contract With One Of The Nation's Leading Providers Of Kidney Care Services, Expanding Access To Vafseo For Patients On Dialysis; The Contract Enables Physicians To Prescribe Vafseo To Patients On Dialysis As Deemed Clinically Appropriate;' Akebia Expects Vafseo Will Be Available In The U.S. In January 2025.

Designed to help dialysis organizations incorporate new treatments into their practices, TDAPA provides two years of reimbursement in addition to the ESRD bundled rate
A HCPCS code has also been assigned to Vafseo to facilitate reimbursement at dialysis organizations
CAMBRIDGE, Mass., Oct. 10, 2024 /PRNewswire/ -- Akebia Therapeutics&#xAE;, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AKBA#NASDAQ">AKBA</a>), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, today announced that the Center for Medicare &amp; Medicaid Services (CMS) has determined that Vafseo&#xAE; (vadadustat)&nbsp;meets the criteria for the Transitional Drug Add-On Payment Adjustment (TDAPA) in the anemia management end-stage renal disease (ESRD) prospective payment system functional category, beginning on January 1, 2025. In March 2024, Vafseo was approved by the U.S. Food and Drug Administration for the treatment of anemia due to chronic kidney disease in adults who have been receiving dialysis for at least three months, and the product is expected to be available in the market in January 2025. The TDAPA program provides two years of reimbursement for Vafseo in addition to the ESRD bundled rate to dialysis organizations.

Akebia Therapeutics Announces The CMS Has Determined That Vafseo Meets The Criteria For The Transitional Drug Add-On Payment Adjustment In The Anemia Management End-Stage Renal Disease Prospective Payment System Functional Category, Beginning On January 1, 2025.

Contracts

Akebia Therapeutics And U.S. Renal Care Sign Supply Contract Enabling USRC Attending Physicians To Prescribe Vafseo For Patients On Dialysis As Deemed Clinically Appropriate

Akebia Therapeutics And U.S. Renal Care Announce Collaborative Clinical Trial To Study Vafseo In Kidney Disease Patients, Aiming To Assess Mortality And Hospitalization Compared To Standard Care​

Akebia Therapeutics shares are trading higher after HC Wainwright & Co. maintained a Buy rating on the stock and raised its price target from $6 to $7.5.

HC Wainwright &amp; Co. analyst Ed Arce maintains Akebia Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AKBA#NASDAQ">AKBA</a>) with a Buy and raises the price target from $6 to $7.5.

HC Wainwright & Co. Maintains Buy on Akebia Therapeutics, Raises Price Target to $7.5

Akebia Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AKBA#NASDAQ">AKBA</a>) reported quarterly losses of $(0.04) per share which beat the analyst consensus estimate of $(0.05) by 20 percent. This is a 33.33 percent increase over losses of $(0.06) per share from the same period last year. The company reported quarterly sales of $43.648 million which missed the analyst consensus estimate of $49.450 million by 11.73 percent. This is a 22.58 percent decrease over sales of $56.376 million the same period last year.

Earnings Beats

Akebia Therapeutics Q2 2024 GAAP EPS $(0.04) Beats $(0.05) Estimate, Sales $43.648M Miss $49.450M Estimate

<ul>
<li>Under the terms of the agreement, CSL Vifor is entitled to quarterly tiered royalty payments ranging from a high single-digit percentage on annual net sales up to $450 million to a mid-single digit percentage on annual net sales above $450 million. Akebia has the opportunity to buy down the royalty agreement beginning on July 1, 2027 with a one-time payment to CSL Vifor, which would decrease the royalty payments to a mid-single digit percentage of Akebia&#39;s annual net sales of Vafseo up to $450 million and eliminate the royalty payment on annual net sales above $450 million.&nbsp;</li>
<li>Announced&nbsp;Vafseo WAC pricing of $1,278 for a 30-day supply</li>
<li>Submitted&nbsp;TDAPA application for Vafseo in June 2024 and expects designation on January 1, 2025</li>
</ul>

Health Care

CSLLY

Akebia And CSL Vifor Have Terminated The License Agreement Providing For The Payment Of Royalties By Akebia To CSL Vifor On Vafseo (Vadadustat) U.S. Net Product Sales. As A Result, Akebia Regained Full Rights To Sell Vafseo In The U.S.

Management

Akebia Therapeutics Announced Erik Ostrowski As Senior Vice President, Chief Financial Officer And Chief Business Officer

Akebia Therapeutics shares are trading lower after the company reported worse-than-expected Q1 financial results.

Akebia Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AKBA#NASDAQ">AKBA</a>) reported quarterly losses of $(0.09) per share which missed the analyst consensus estimate of $(0.08) by 12.5 percent. The company reported quarterly sales of $32.607 million which missed the analyst consensus estimate of $46.087 million by 29.25 percent.&nbsp;

Akebia Therapeutics Q1 2024 GAAP EPS $(0.09) Misses $(0.08) Estimate, Sales $32.607M Miss $46.087M Estimate

<h3>Gainers</h3>
<ul>
<li>IN8bio (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INAB#NASDAQ">INAB</a>) stock increased by 47.7% to $1.61 during Wednesday's pre-market session. The market value of their outstanding shares is at $69.6 million. </li>
<li>Jaguar Health (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/JAGX#NASDAQ">JAGX</a>) shares rose 25.0% to $0.11. The company's market cap stands at $31.0 million. </li>
<li>China SXT Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SXTC#NASDAQ">SXTC</a>) shares moved upwards by 24.85% to $2.16. The market value of their outstanding shares is at $1.2 million. </li>
<li>Adial Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ADIL#NASDAQ">ADIL</a>) shares increased by 23.06% to $1.39. The market value of their outstanding shares is at $5.6 million. </li>
<li>iSpecimen (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ISPC#NASDAQ">ISPC</a>) stock increased by 13.96% to $0.24. The company's market cap stands at $2.1 million. </li>
<li>Akebia Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AKBA#NASDAQ">AKBA</a>) stock increased by 11.03% to $1.71. The market value of their outstanding shares is at $358.0 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>BioSig Technologies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BSGM#NASDAQ">BSGM</a>) shares fell 13.0% to $1.41 during Wednesday's pre-market session. The market value of their outstanding shares is at $13.1 million. </li>
<li>Cocrystal Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/COCP#NASDAQ">COCP</a>) shares fell 10.97% to $1.38. The company's market cap stands at $14.0 million. </li>
<li>Synaptogenix (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SNPX#NASDAQ">SNPX</a>) shares declined by 8.52% to $4.52. The company's market cap stands at $4.9 million. </li>
<li>Kineta (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KA#NASDAQ">KA</a>) stock fell 7.12% to $0.4. The market value of their outstanding shares is at $4.3 million. </li>
<li>Biophytis (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BPTS#NASDAQ">BPTS</a>) stock declined by 6.57% to $0.39. The company's market cap stands at $4.4 million. </li>
<li>Addex Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ADXN#NASDAQ">ADXN</a>) shares decreased by 6.42% to $26.11. The market value of their outstanding shares is at $27.6 million. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Movers

ADIL

ADXN

BPTS

BSGM

COCP

INAB

ISPC

JAGX

SNPX

SXTC

12 Health Care Stocks Moving In Wednesday's Pre-Market Session

Akebia (AKBA) Therapeutics announced that it has signed a multi-year commercial contract with one of the nation's leading providers of kidney care ...

Akebia signs commercial supply contract with dialysis organization

Get caught up quickly on the top news and calls moving stocks with these five Top Five lists. 1. STOCK NEWS: GE Aerospace (GE) reported upbeat Q3 e...

GE Aerospace, GM report quarterly earnings beats: Morning Buzz

H.C. Wainwright analyst Ed Arce maintained a Buy rating on Akebia Therapeutics (AKBA – Research Report) today and set a price target of $7.50. Ed A...

Akebia Therapeutics: Strategic Developments and Financial Outlook Drive Buy Rating

These names in the biotech sector are seeing a substantial increase in search activity today, as determined by InvestingChannel. They include:&nbsp...

Biotech Alert: Searches spiking for these stocks today

Akebia Q3 2024 Earnings Preview

Akebia GAAP EPS of -$0.10, revenue of $37.4M

Akebia Therapeutics, Inc. (AKBA) Q3 2024 Earnings Call Transcript

Akebia Therapeutics ( ($AKBA) ) has released its Q3 earnings. Here is a breakdown of the information Akebia Therapeutics presented to its investors...

Akebia Therapeutics Prepares for Vafseo Launch

Piper Sandler analyst Allison Bratzel maintained a Buy rating on Akebia Therapeutics (AKBA – Research Report) today and set a price target of $4.00...

Piper Sandler Sticks to Its Buy Rating for Akebia Therapeutics (AKBA)

Q3 2024 Earnings: Hold Akebia Therapeutics

ALLK

CAKE

CNSP

COHR

CRMD

CSIQ

CYCC

DBVT

FDMT

FSLR

GNPX

HNDAF

HSBC

IMUX

LOGI

LRMR

MBIO

PRME

SGMO

UBER

UBSFY

Press Releases

Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Akebia Therapeutics and U.S. Renal Care Sign Commercial Supply Contract to Enable Access to Vafseo® (vadadustat) for Patients on Dialysis

CMS Grants TDAPA Reimbursement for Vafseo® (vadadustat) beginning January 1, 2025

Akebia Therapeutics Announces Seven Poster Presentations at ASN Kidney Week 2024

Akebia Therapeutics Signs Commercial Supply Contract with Leading Dialysis Organization to Enable Access to Vafseo® (vadadustat) for Patients on Dialysis

Akebia Therapeutics to Report Third Quarter 2024 Financial Results and Discuss Recent Business Highlights

Akebia Therapeutics Reports Third Quarter 2024 Financial Results and Recent Business Highlights

Akebia Therapeutics to Present at the Jefferies London Healthcare Conference

Vadadustat Alternative Dosing Study Results Published in the American Journal of Kidney Disease

Comments

Akebia Therapeutics

Vendite allo scoperto

Akebia Therapeutics (NASDAQ:AKBA) Azioni, Report sulle vendite allo scoperto

Le persone guardano anche

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO